All In Biotech

Drug Trial Radar · NCT00811720

Efficacy of Nalmefene in Patients With Alcohol Dependence

Nalmefene Efficacy Study I: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, As-needed Use, in Patients With Alcohol Dependence

Last checked: Nov 20, 2026Latest source record: Jul 9, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 598 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

598

Actual

Start

Dec 2008

Primary completion

Oct 2010

Study completion Nov 2010

Sponsor

Lead sponsor
H. Lundbeck A/SIndustry
Sponsor type
Industry
First posted
Dec 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.

Conditions

  • Alcohol Dependence

Interventions

  • PlaceboDrug

    as-needed use, tablets, orally, 6 months

  • NalmefeneDrug

    18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)Time frame: Baseline and Month 6
  2. Change From Baseline in the Monthly Total Alcohol Consumption (TAC)Time frame: Baseline and Month 6

Locations

39 sites in 4 countries. Site status is shown where the registry gives one.

  • AT001

    Linz, Austria

  • AT004

    Salzburg, Austria

  • AT003

    Vienna, Austria

  • AT002

    Vienna, Austria

  • FI008

    Helsinki, Finland

  • FI009

    Helsinki, Finland

  • FI007

    Jarvenpaa, Finland

  • FI013

    Kuopio, Finland

  • FI004

    Kuusankoski, Finland

  • FI001

    Mikkeli, Finland

  • FI015

    Oulu, Finland

  • FI003

    Tampere, Finland

  • FI002

    Tampere, Finland

  • FI014

    Turku, Finland

  • FI011

    Vantaa, Finland

  • DE011

    Bad Saarow, Germany

  • DE016

    Berlin, Germany

  • DE005

    Berlin, Germany

  • DE002

    Berlin, Germany

  • DE017

    Berlin, Germany

  • DE008

    Berlin, Germany

  • DE019

    Berlin, Germany

  • DE003

    Essen, Germany

  • DE006

    Hamburg, Germany

  • DE001

    Hamburg, Germany

  • DE007

    Leukersdorf, Germany

  • DE003

    Mannheim, Germany

  • DE014

    Munich, Germany

  • DE010

    Regensburg, Germany

  • DE018

    Siegen, Germany

  • DE020

    Wallerfing, Germany

  • SE011

    Gothenburg, Sweden

  • SE005

    Kalmar, Sweden

  • SE006

    Linköping, Sweden

  • SE001

    Malmö, Sweden

  • SE004

    Stockholm, Sweden

  • SE002

    Stockholm, Sweden

  • SE008

    Stockholm, Sweden

  • SE009

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.